SCHEMBL167981

SCHEMBL167981

O=Cc1cc(OCc2ccc(F)cc2)c(C(=O)OCc2ccc(F)cc2)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.49
MAPT P10636 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
FFAR4 Q5NUL3 2/20 0.44
FFAR1 O14842 1/20 0.44
KDM4E B2RXH2 2/20 0.42
PTPN7 P35236 1/20 0.42
PTPN12 Q05209 1/20 0.42
PTPN22 Q9Y2R2 1/20 0.42
MAOB P27338 4/20 0.41
MAOA P21397 2/20 0.41
PTPN1 P18031 3/20 0.40
CCR5 P51681 1/20 0.40
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
NR4A2 P43354 1/20 0.39
CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167521 0.88 ALDH1A1 (0.48) LMNAMAPTL3MBTL1ALDH1A1HPGD
SCHEMBL165606 0.81 FFAR4 (0.48) LMNAMAPTL3MBTL1ALDH1A1FFAR4
SCHEMBL1647807 0.80 MAOA (0.52) LMNAMAPTL3MBTL1ALDH1A1HPGD
SCHEMBL1648521 0.79 LRRK2 (0.56) LMNAMAPTL3MBTL1SMN1; SMN2FFAR4
SCHEMBL167731 0.74 NPC1 (0.46) LMNAMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL167389 0.73 CCR5 (0.48) LMNAMAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL5631333 0.73 MAOA (0.51) MAPTL3MBTL1ALDH1A1FFAR4FFAR1
SCHEMBL165429 0.73 POLB (0.52) L3MBTL1ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL382869 0.73 ALDH1A1 (0.53) L3MBTL1ALDH1A1SMN1; SMN2KDM4ERAB9A
SCHEMBL31363007 0.73 ALDH1A1 (0.53) L3MBTL1ALDH1A1SMN1; SMN2KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 LMNA 1687/4885MAPT 102/4885L3MBTL1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.